Comparative Pharmacology
Head-to-head clinical analysis: CRISABOROLE versus DALIRESP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRISABOROLE versus DALIRESP.
CRISABOROLE vs DALIRESP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Crisaborole is a phosphodiesterase 4 (PDE4) inhibitor. It reduces the production of proinflammatory cytokines by inhibiting PDE4-mediated degradation of cyclic adenosine monophosphate (cAMP), leading to decreased inflammation in the skin.
Selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammation by increasing intracellular cAMP levels, thereby inhibiting inflammatory cell activity.
Intravenous: 0.25 mg/m² over 30 minutes on Days 1, 2, and 8, 9 of a 21-day cycle. Premedicate with antiemetics. For acute promyelocytic leukemia, 0.25 mg/m² on Days 1, 2, 8, 9 of a 28-day cycle.
500 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is approximately 5 hours (range 3-8 hours) in healthy subjects; no clinically relevant accumulation with once-daily dosing.
Clinical Note
moderateMeloxicam + Crisaborole
"The metabolism of Crisaborole can be decreased when combined with Meloxicam."
Clinical Note
moderateCyclophosphamide + Crisaborole
"The metabolism of Crisaborole can be decreased when combined with Cyclophosphamide."
Clinical Note
moderatePaclitaxel + Crisaborole
"The metabolism of Crisaborole can be decreased when combined with Paclitaxel."
Clinical Note
moderateCabazitaxel + Crisaborole
The terminal elimination half-life is approximately 17-21 hours, supporting once-daily dosing.
Primarily hepatic metabolism (CYP3A4 and CYP2D6) with renal excretion of metabolites: unchanged drug <1% in urine; fecal excretion accounts for approximately 60% of the dose.
Approximately 70% of the dose is excreted via the feces (primarily as unchanged drug and glucuronide conjugates) and 20% via the urine (mostly as metabolites).
Category C
Category C
Phosphodiesterase-4 Inhibitor
Phosphodiesterase-4 Inhibitor
"The metabolism of Crisaborole can be decreased when combined with Cabazitaxel."